Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: combined growth hormone secretagogue signaling
Also known as: CJC DAC/IPA
This entry is a multi-compound blend. Each component can be opened individually in the reconstitution calculator.
Component amounts shown are arithmetic starters based on equal distribution. Edit values in the calculator before saving.
This fixed blend combines long-acting CJC-1295 DAC with ipamorelin. The components act at different receptors but have mismatched pharmacokinetics. No controlled human trial validates the combined formulation ratio dose schedule compatibility or safety.
Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.
Data source: Component human studies, FDA review, and current fixed-blend market listings
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.
A 10 mg total equal-ratio blend is marketed but no controlled study supports combining the long-acting DAC analog with short-acting ipamorelin.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention CJC-1295 DAC + Ipamorelin or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.